DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 1, 2006; DOI: 10.1124/dmd.106.011817


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.011817v1
35/2/321    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahan, A.
Right arrow Articles by Hoffman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahan, A.
Right arrow Articles by Hoffman, A.


Received for publication July 5, 2006.
Revised November 27, 2006.
Accepted for publication November 28, 2006.

MODE OF ADMINISTRATION DEPENDENT BRAIN UPTAKE OF INDOMETHACIN: SUSTAINED SYSTEMIC INPUT INCREASES BRAIN INFLUX

Arik Dahan 1 Amnon Hoffman 1*

1 The Hebrew University of Jerusalem

* Address correspondence to: E-mail: ahoffman{at}cc.huji.ac.il

Abstract

NSAIDs, including indomethacin, have been found in both epidemiological and clinical studies to reduce the prevalence and severity of Alzheimer's disease. However, long-term use of indomethacin is limited by significant gastrointestinal and renal toxicities. An indomethacin prodrug that delivers low and continuous blood levels of the drug showed a superior safety profile and similar efficacy in comparison to equivalent dose of free indomethacin due to limited systemic exposure and preferred brain uptake. The purpose of the present investigation was to evaluate whether sustained systemic input causes an increased brain influx in comparison to rapid input of the drug. Oral indomethacin, indomethacin prodrug or intravenous indomethacin infusion were administered to rats. The infusion was designed to mimic the plasma indomethacin levels resulting from the prodrug. The resultant blood levels and brain indomethacin uptake were evaluated. The brain indomethacin concentrations 8 hours after indomethacin administration were 0.45, 0.3 and 0.31µg/g following the oral indomethacin, oral prodrug and the intravenous infusion, respectively. The corresponding plasma concentrations were 14.1, 4.1 and 4µg/ml. Therefore, brain vs. plasma indomethacin levels ratios were 2.5-fold higher following slow systemic input of indomethacin in comparison to rapid drug input. In conclusion, indomethacin brain uptake was found to be mode of administration dependent, and a sustained input function increases the drug brain uptake. Thus, these unique results indicate that an appropriate indomethacin controlled release delivery system may induce the desirable brain related pharmacodynamic effects, while avoiding the concentration dependent adverse effects. These findings may contribute to improved therapy in Alzheimer’s disease.


Key words: blood-CNS transport, controlled drug release, drug delivery, pharmacokinetics





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.